進階篩選

Technical category
    • Application of inorganic nanofiber technology to promote the development of biotechnology

      Smart machinerynovel materials FutureTech Application of inorganic nanofiber technology to promote the development of biotechnology

      Inorganic porous nanofibers with surfaceinterface defects are prepared through humidity-controlled electrospinninghigh-temperature annealing technology. Under the irradiation of light sources of different wavelengths (380~780 nm), the bound electrons stored in the valence band can be excited to the conduction band to form free electrons on the surface of the material, generating different intensities of microcurrents, light sensitivitymicrocurrent changes. Because the "inorganic nanofiber" technology has high uniquenesshigh product compatibility, it can be applied to a wide range of markets.
    • (test)Application of inorganic nanofiber technology to promote the development of biotechnology

      Smart machinerynovel materials FutureTech (test)Application of inorganic nanofiber technology to promote the development of biotechnology

      Inorganic porous nanofibers with surfaceinterface defects are prepared through humidity-controlled electrospinninghigh-temperature annealing technology. Under the irradiation of light sources of different wavelengths (380~780 nm), the bound electrons stored in the valence band can be excited to the conduction band to form free electrons on the surface of the material, generating different intensities of microcurrents, light sensitivitymicrocurrent changes. Because the "inorganic nanofiber" technology has high uniquenesshigh product compatibility, it can be applied to a wide range of markets.
    • 新冠肺炎病毒以及其變異株的單醣化棘突蛋白疫苗

      FutureTech 新冠肺炎病毒以及其變異株的單醣化棘突蛋白疫苗

      Monoglycosylated spike protein vaccine provides better protection against infections of SARS-CoV-2its variants of concern. Spike protein, which is the main immunogen in all current vaccines, is heavily glycosylatedthe epitopes covered by glycans are usually less immunogenic. Monoglycosylated spike protein vaccine, when vaccinated, can elicit better immune response with a more complete protection against all possible epitopes from spike polypeptide sequence,provide better protection against infections from variants of concerns.
    • 新冠肺炎相關研究小鼠小鼠模式之建構

      FutureTech 新冠肺炎相關研究小鼠小鼠模式之建構

      Our core generated several types of transgenic micea stable humanized ACE2 mice using a combi-CRISPR genetic engineering technique. We hope these mouse models can help to dissect COVID-19 pathogenic mechanismthe interaction(s) between spike proteinACE2 K353.
    • BPRSJ338: Therapeutic Applications for COVID-19

      Precision Health Ecosystem FutureTech BPRSJ338: Therapeutic Applications for COVID-19

      BPRSJ338 exhibits high potency of anti-SARS-CoV-2 activity and is in development for fighting COVID-19 as a first-in-class drug. BPRSJ338 also potently inhibits against broad-spectrum coronaviruses including SARS-CoV-2, SARS-CoV, HCoV-229E, HCoV-OC43, TGEV, FIPV and MHV. Related US and Taiwan patents have been granted.​ Therefore it is also applicable to fight against severe evolving coronaviruses in the future.
    • Building A Deep Learning-based Chest X-ray CADe Platform MedCheX

      Precision Health Ecosystem FutureTech Building A Deep Learning-based Chest X-ray CADe Platform MedCheX

      As we continue to face the rapid increase in confirmed Coronavirus cases around the world, we created an AI-based pneumonia detection platform for COVID-19. The system is able to automatically detect high-risk patients with pneumonia that will then send information to doctors. With that information, the doctors are then able to make follow-up decisions and provide a treatment plan after the diagnosis. In specific, doctors from the Department of Medical Imaging provided us thousands of positive and negative chest x-rays for pneumonia as a training set. Our system has already been tested with and adopted by doctors at the NCKU Hospital. The system achieved 95% accuracy to detect the pneumonia symptom, based on 1400 test images.
    • Development of NRICM101 - A Novel Anti-COVID-19 TCM Therapy

      FutureTech Development of NRICM101 - A Novel Anti-COVID-19 TCM Therapy

      NRICM101 has revealed positive outcome in COVID-19 treatment clinically. Pharmacological studies have confirmed that it can neutralize the SARS-CoV-2, block virus infection, inhibit virus growth,reduce the occurrence of cytokine storms. NRICM101 has been non-exclusively authorized by 8 Taiwanese GMP-certified TCM pharmaceuticals. At present, NRICM101 is seeing an increasing worldwide demand,has received Emergency Use Authorization from the Ministry of HealthWelfare of Taiwan. Asymptomaticmildly ill patients of COVID-19 are expected to benefit from it.
    • 以幾丁聚醣鼻噴劑促進嗅覺神經上皮再生治療嗅覺失常

      FutureTech 以幾丁聚醣鼻噴劑促進嗅覺神經上皮再生治療嗅覺失常

      The prevalence of olfactory dysfunction increases significantly in recent years. More than 35 patients with COVID-19 have sequelae of olfactory dysfunction after recovery. However, there are no effective treatments for sensorineural olfactory dysfunction to date. This is the first report demonstrates that chitosan can promote differentiation of olfactory receptor neuronsregenerate olfactory neuroepithelium. Further intranasal administration of chitosan will be developed for treating olfactory dysfunction.
    • 治療多種癌症與纖維化之首創抗體新藥

      FutureTech 治療多種癌症與纖維化之首創抗體新藥

      Ninety percent of human diseases are related to abnormal inflammation. WJM team has successfully developed a new monoclonal antibody that can inhibit a key inflammation protein. Animal experiments have accumulated more than ten disease modes, including a variety of solid tumors, fibrosis, degenerativecardiovascular diseases. This antibody is qualified as an orphan drug for the treatment of IPF. New coronary pneumonia has greatly increased the demand for pulmonary fibrosis treatment,has also become an important target for mergersacquisitions of global pharmaceutical companies.
    • 測溫式側流免疫分析法和檢測儀

      FutureTech 測溫式側流免疫分析法和檢測儀

      We have developed a low-costportable reader for thermometric lateral flow immunoassay (TLFIA) using colloidal goldlatex beads as reportersa continuous-wave green laser as the heating source. Instead of using infrared cameras, a single-element infrared sensor is employed for temperature sensing without compromising the sensitivity of the reader. The thermometric assay provides a 10× higher sensitivity than color visualizationthe results are sufficiently quantitative to support decision making in point-of-care testing for infectious diseases (such as COVID-19).
    • 智慧型電化學阻抗生物感測晶片平台

      FutureTech 智慧型電化學阻抗生物感測晶片平台

      Our technology combines optimized semiconductor manufacturing technique with unique biomediator preparation to achieve the first reliable POC biosensing platform. Sensors developed according to this method possess reproducibility, accuracy,stability that meet POC. Our sensors are portable, require low sample volume, do not require sample processing,are extremely suitable for use in POC settings. They can also be integrated into IoT systems to aide in rapid decision making,can be mass produced. Overall, we are the first to achieve accessible, reliable detection at the POC.
    • 結合虛擬實境與慣性姿態感測器之防疫機器代理人

      FutureTech 結合虛擬實境與慣性姿態感測器之防疫機器代理人

      We have designed a remotely-controlled robot which equipped with a 360 degree full HD camera. User’s postures are detected by measuring the accelerationrotation of changes of limb postures using inertial measurement units (IMU). User’s motion commands are wirelessly transmitted to actuate the remote robot in accordance with user’s posture. The 360 degree full scene camera keeps transmitting the real-time situation of the scene surrounding the robot back to the user, displayed on the VR headset.